Opendata, web and dolomites

LiverScreen SIGNED

Screening for liver fibrosis - population-based study across European countries

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LiverScreen" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA 

Organization address
address: CARRER ROSSELLO 149
city: BARCELONA
postcode: 8036
website: www.fundacioclinic.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 5˙996˙481 €
 EC max contribution 5˙996˙481 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) coordinator 1˙205˙000.00
2    ODENSE UNIVERSITETSHOSPITAL DK (ODENSE) participant 650˙000.00
3    UNIVERSITAT DES SAARLANDES DE (SAARBRUCKEN) participant 649˙962.00
4    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 449˙530.00
5    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 432˙991.00
6    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 340˙000.00
7    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 315˙000.00
8    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 314˙000.00
9    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 313˙750.00
10    GENESIS BIOMED ES (BARCELONA) participant 233˙750.00
11    SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET HR (ZAGREB) participant 225˙000.00
12    INNOVATION ACTA S.R.L. IT (ROMA) participant 221˙375.00
13    CONSORCIO MAR PARC DE SALUT DE BARCELONA ES (BARCELONA) participant 127˙372.00
14    BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION ES (BARCELONA) participant 120˙000.00
15    UNIVERSIDAD POMPEU FABRA ES (BARCELONA) participant 118˙750.00
16    AZIENDA OSPEDALE UNIVERSITA PADOVA IT (PADOVA) participant 100˙000.00
17    ECHOSENS FR (PARIS) participant 90˙000.00
18    EUROPEAN LIVER PATIENTS ASSOCIATION BE (BRUXELLES) participant 55˙000.00
19    EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER CH (ZURICH) participant 35˙000.00

Map

 Project objective

Liver cirrhosis is a very common and severe chronic disease, responsible for high morbidity, impaired quality of life, major healthcare costs, and poor survival, causing an estimated 170,000 deaths per year in Europe. Liver cirrhosis is preceded by a long period of slowly developing, asymptomatic, liver fibrosis; most commonly caused by non-alcoholic fatty liver disease (NAFLD, related to obesity and type 2 diabetes), alcohol, and hepatitis B or C virus infection. There is no treatment available to reverse advanced liver cirrhosis. However, if fibrosis could be detected early, all of the major causes are still amenable to prevention and treatment. Early diagnosis of liver fibrosis in the general population is therefore crucial for the estimated 10 million Europeans with undetected liver fibrosis.

The LiverScreen project aims to develop a targeted screening methodology to identify persons with asymptomatic liver fibrosis and cirrhosis among the general population. This methodology involves: 1) identification of groups from the general population at high risk of having chronic liver disease, 2) screening their liver stiffness with the innovative transient elastography (TE) technology (until now only validated in patients with known liver disease) for diagnosis, and 3) determining the right follow-up screening regime. Within the LiverScreen project 8 European countries will collaborate and perform research in over 34,000 subjects to develop the screening methodology and demonstrate its accuracy, clinical value, cost-effectiveness, acceptability, and potential to be implemented by healthcare systems throughout Europe.

Using the LiverScreen program, diagnosis at an early stage can stop liver disease progression and have a subsequent long-term impact on liver disease morbidity and mortality and the associated societal burdens in terms of economic costs and health inequity. The estimated cost reduction ranges from €850 to €4,000 per quality-adjusted life-year gained.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIVERSCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIVERSCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

ENDFLU (2020)

Evaluation of ratioNally Designed Influenza vaccines

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More